Compare AANJANEYA LIFECARE with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs GSK PHARMA - Comparison Results

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS GSK PHARMA DR. DATSONS LABS/
GSK PHARMA
 
P/E (TTM) x -10.9 51.3 - View Chart
P/BV x 0.2 10.8 1.5% View Chart
Dividend Yield % 0.0 1.5 -  

Financials

 DR. DATSONS LABS   GSK PHARMA
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
GSK PHARMA
Mar-19
DR. DATSONS LABS/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1263,595 3.5%   
Low Rs311,253 2.5%   
Sales per share (Unadj.) Rs133.0184.7 72.0%  
Earnings per share (Unadj.) Rs0.226.3 0.6%  
Cash flow per share (Unadj.) Rs6.629.2 22.7%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs128.8126.3 102.0%  
Shares outstanding (eoy) m31.66169.40 18.7%   
Bonus/Rights/Conversions FCCB--  
Price / Sales ratio x0.613.1 4.5%   
Avg P/E ratio x516.192.2 559.8%  
P/CF ratio (eoy) x11.883.1 14.2%  
Price / Book Value ratio x0.619.2 3.2%  
Dividend payout %076.1 0.0%   
Avg Mkt Cap Rs m2,477410,626 0.6%   
No. of employees `000NA5.0 0.0%   
Total wages/salary Rs m565,372 1.0%   
Avg. sales/employee Rs ThNM6,306.7-  
Avg. wages/employee Rs ThNM1,083.1-  
Avg. net profit/employee Rs ThNM898.0-  
INCOME DATA
Net Sales Rs m4,21131,281 13.5%  
Other income Rs m791,023 7.7%   
Total revenues Rs m4,28932,304 13.3%   
Gross profit Rs m5696,009 9.5%  
Depreciation Rs m204486 42.1%   
Interest Rs m4306 7,170.0%   
Profit before tax Rs m136,540 0.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m62,373 0.3%   
Profit after tax Rs m54,454 0.1%  
Gross profit margin %13.519.2 70.3%  
Effective tax rate %48.036.3 132.4%   
Net profit margin %0.114.2 0.8%  
BALANCE SHEET DATA
Current assets Rs m6,85220,061 34.2%   
Current liabilities Rs m6,71114,543 46.1%   
Net working cap to sales %3.317.6 19.0%  
Current ratio x1.01.4 74.0%  
Inventory Days Days16157 283.3%  
Debtors Days Days31814 2,265.1%  
Net fixed assets Rs m3,67314,343 25.6%   
Share capital Rs m3171,694 18.7%   
"Free" reserves Rs m3,76119,704 19.1%   
Net worth Rs m4,07821,398 19.1%   
Long term debt Rs m1,6712 83,540.0%   
Total assets Rs m12,63339,113 32.3%  
Interest coverage x1.01,091.0 0.1%   
Debt to equity ratio x0.40 438,409.1%  
Sales to assets ratio x0.30.8 41.7%   
Return on assets %3.411.4 30.2%  
Return on equity %0.120.8 0.6%  
Return on capital %7.731.9 24.0%  
Exports to sales %22.90-   
Imports to sales %14.30-   
Exports (fob) Rs m964NA-   
Imports (cif) Rs m602NA-   
Fx inflow Rs m964534 180.5%   
Fx outflow Rs m6077,091 8.6%   
Net fx Rs m357-6,557 -5.4%   
CASH FLOW
From Operations Rs m1,3453,994 33.7%  
From Investments Rs m-2,256-1,433 157.4%  
From Financial Activity Rs m-1,200-3,584 33.5%  
Net Cashflow Rs m-2,111-1,023 206.3%  

Share Holding

Indian Promoters % 4.5 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 0.0 10.2 -  
FIIs % 1.4 23.8 5.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 15.4 611.0%  
Shareholders   20,807 102,036 20.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  FULFORD INDIA  NATCO PHARMA  AJANTA PHARMA  

Compare DR. DATSONS LABS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Strengthening Rupee, Inflation & Factory Output Data, and Top Stocks in Action Today(Pre-Open)

On Friday, Indian share markets witnessed most of the buying interest during closing hours and ended on a strong note.

Related Views on News

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

MSTC IPO: Should You Bet on This State-Run E-Commerce Player? (IPO)

Mar 13, 2019

Should you subscribe to the IPO of MSPC Limited?

GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 26.0% (Quarterly Result Update)

Feb 5, 2019 | Updated on Feb 5, 2019

For the quarter ended December 2018, GSK PHARMA has posted a net profit of Rs 1 bn (up 26.0% YoY). Sales on the other hand came in at Rs 8 bn (up 17.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS - STERLING BIOTECH COMPARISON

COMPARE DR. DATSONS LABS WITH

MARKET STATS